Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Maj Jožef, Igor Locatelli, Gregor Brecl Jakob, Mitja Kos & Uroš Rot. (2023) Medication persistence among people with multiple sclerosis in Slovenia treated with dimethyl fumarate. Current Medical Research and Opinion 39:11, pages 1489-1496.
Read now
Read now
Andrea Zimmer, Michael Coslovsky, Ivo Abraham & Bernhard F Décard. (2017) Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study. Patient Preference and Adherence 11, pages 1815-1830.
Read now
Read now
María Dolores Edo Solsona, Emilio Monte Boquet, Bonaventura Casanova Estruch & José Luis Poveda Andrés. (2017) Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis. Patient Preference and Adherence 11, pages 415-421.
Read now
Read now
Articles from other publishers (20)
Malte Roar, Amalie Rhode Høgh Nielsen, Jonas Munksgaard Berg, Georgi Sirakov, Morten Stilund, Jakob Schäfer, Rikke Ratzer, Jette Frederiksen, Nasrin Asgari, Said Nasim Ashna, Henrik Boye Jensen, Matthias Kant, Ásta Theódorsdóttir, Zsolt Illes, Finn Sellebjerg, Melinda Magyari, Louise Mose Schlosser, Hilde Nordborg, Stig Wergeland & Tobias Sejbaek. (2023) Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study. Multiple Sclerosis and Related Disorders 80, pages 105127.
Crossref
Crossref
Clara López-Caneda, María José Pérez-Haro, César Sánchez-Franco, Elena Álvarez-Rodríguez, Marta Aguado-Valcárcel, María Marcos-Bobillo & Inés González-Suarez. (2023) Real-world persistence to first-line DMTs in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 78, pages 104909.
Crossref
Crossref
Aliza Bitton Ben-Zacharia, Bryan Walker, Amy Perrin Ross, Carlo Tornatore, Natalie C. Edwards, Yvette Lipman & Amy L. Phillips. (2023) Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review. International Journal of MS Care 25:5, pages 188-195.
Crossref
Crossref
Chun-Ming Liao, Wei-Yin Kuo, Pei-Tseng Kung, Chuang-Hui Chuan & Wen-Chen Tsai. (2022) Epidemiological investigation of multiple sclerosis and related medical utilisation in Taiwan. Multiple Sclerosis Journal 28:8, pages 1198-1208.
Crossref
Crossref
Miranda Z. Kozlicki, Brandon Markley, Nisha B. Shah, Josh DeClercq, Leena Choi & Autumn D. Zuckerman. (2022) A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy. Multiple Sclerosis and Related Disorders 63, pages 103860.
Crossref
Crossref
Elizabeth S. Gromisch, Aaron P. Turner, Steven L. Leipertz, Lindsay O. Neto, John Beauvais & Jodie K. Haselkorn. (2022) Comorbidities as predictors of all-cause emergency department utilization among veterans with multiple sclerosis. Multiple Sclerosis and Related Disorders 62, pages 103806.
Crossref
Crossref
Marcello Moccia, Giuseppina Affinito, Bruno Ronga, Roberta Giordana, Maria Grazia Fumo, Roberta Lanzillo, Maria Petracca, Antonio Carotenuto, Maria Triassi, Vincenzo Brescia Morra & Raffaele Palladino. (2022) Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy). Multiple Sclerosis Journal 28:4, pages 597-607.
Crossref
Crossref
Gabriel Pardo, Elmor D. Pineda, Carmen D. Ng, Komal K. Bawa, Daniel Sheinson & Nicole G. Bonine. (2022) Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis. Neurology and Therapy 11:1, pages 337-351.
Crossref
Crossref
Brant J. Oliver, Karen WalshRandall Messier, Falguni MehtaAnn CabotEric KlawiterPatricia PagnottaAndrew SolomonSarah E. England. (2022) System-Level Variation in Multiple Sclerosis Care Outcomes: Initial Findings from the Multiple Sclerosis Continuous Quality Improvement Research Collaborative. Population Health Management 25:1, pages 46-56.
Crossref
Crossref
Natalie J EngmannDanny SheinsonKomal BawaCarmen D NgGabriel Pardo. (2021) Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. Journal of Managed Care & Specialty Pharmacy 27:5, pages 639-649.
Crossref
Crossref
Gurpreet K Reen, Eli Silber & Dawn W Langdon. (2021) Improving MS patients’ understanding of treatment risks and benefits in clinical consultations: A randomised crossover trial. Multiple Sclerosis and Related Disorders 49, pages 102737.
Crossref
Crossref
Jacqueline A. Nicholas, Natalie C. Edwards, Roger A. Edwards, Anna Dellarole, Megan Grosso & Amy L. Phillips. (2020) Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. BMC Neurology 20:1.
Crossref
Crossref
Elise Jonasson & Tobias Sejbaek. (2020) Diroximel fumarate in the treatment of multiple sclerosis. Neurodegenerative Disease Management 10:5, pages 267-276.
Crossref
Crossref
Adys MendizabalDylan P. ThibaultJames A. CrispoAdina PaleyAllison W. Willis. (2020) Comorbid disease drives short-term hospitalization outcomes in patients with multiple sclerosis. Neurology Clinical Practice 10:3, pages 255-264.
Crossref
Crossref
Karly Stratos, Kevin McGarragle, James Thistle, Manav V. Vyas & Liesly Lee. (2020) Non-compliance with disease modifying therapies in patients with Multiple Sclerosis: A qualitative analysis. Multiple Sclerosis and Related Disorders 41, pages 102016.
Crossref
Crossref
Tobias Sejbaek, Mads Nybo, Thor Petersen & Zsolt Illes. (2018) Real-life persistence and tolerability with dimethyl fumarate. Multiple Sclerosis and Related Disorders 24, pages 42-46.
Crossref
Crossref
Marti GroenewegSara H. ForresterBeth ArnoldLorella PalazzoWeiwei ZhuPaul YoonTim Scearce. (2018) One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program. Journal of Managed Care & Specialty Pharmacy 24:5, pages 458-463.
Crossref
Crossref
Daniel Kantor, Kristen Johnson, Maria Cecilia Vieira, James Signorovitch, Nanxin Li, Wei Gao, Valerie Koo, Emilie Duchesneau & Vivian Herrera. (2018) Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis. Journal of the Neurological Sciences 388, pages 168-174.
Crossref
Crossref
Alexander Rae-Grant, Gregory S. Day, Ruth Ann Marrie, Alejandro Rabinstein, Bruce A.C. Cree, Gary S. Gronseth, Michael Haboubi, June Halper, Jonathan P. Hosey, David E. Jones, Robert Lisak, Daniel Pelletier, Sonja Potrebic, Cynthia Sitcov, Rick Sommers, Julie Stachowiak, Thomas S.D. Getchius, Shannon A. Merillat & Tamara Pringsheim. (2018) Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 90:17, pages 777-788.
Crossref
Crossref
J Nicholas, JJ Ko, Y Park, P Navaratnam, HS Friedman, FR Ernst & V Herrera. (2017) Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing–remitting multiple sclerosis patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical 3:1, pages 205521731769611.
Crossref
Crossref